Loading
The validation of a urine test reading two genes, combined with clinical factors, to detect high-grade prostate cancer.
The multimodal approach reached an overall area under the curve of 0.90 (95% CI 0.85 to 0.95) in the validation cohort.
Urine mRNA plus clinical factors separates high-grade from low-grade or no cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares SelectMDx, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker, Prostate cancer.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/